Nexalin Technology Files S-1/A Amendment for IPO
Nexalin Technology, Inc. filed an amended Form S-1/A with the SEC on October 8, 2026, updating its IPO registration. The company develops non-invasive neuromodulation devices. This amendment likely addresses SEC comments, updated financials, or underwriting terms—indicating active progress through the review process.
51CFO view：S-1/A amendments often trigger SEC comment letters requiring CFO-led, cross-functional responses within tight deadlines. For medtech firms, this includes justifying FDA regulatory impact on revenue recognition, R&D capitalization policy under ASC 730, and intercompany cost allocations—all demanding both industry fluency and SEC response experience.
Nexalin Technology, Inc. filed an amended Form S-1/A with the SEC on October 8, 2026, updating its IPO registration. The company develops non-invasive neuromodulation devices. This amendment likely addresses SEC comments, updated financials, or underwriting terms—indicating active progress through the review process.
Source：SEC EDGAR · S-1 招股书备案